Innate Pharma SA Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan Dickinson
- Full Time Employees
- 163
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 117, Avenue de Luminy Marseille PAC France 13009
- IPO Date
- Nov 1, 2006
- Website
- innate-pharma.com
- Similar Companies
- Business
- Innate Pharma S.A. is a clinical-stage biotechnology firm dedicated to the discovery, development, and commercialization of therapeutic antibodies aimed at oncology indications across various international markets. The company leverages its scientific expertise in innate immunity and antibody engineering, including its proprietary ANKET® platform, to generate novel immunotherapies for cancer patients. Within its clinical pipeline, Lacutamab (IPH4102), a first-in-class anti-KIR3DL2 antibody, is advancing. This asset has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Sézary syndrome, and the FDA has cleared the protocol for a confirmatory Phase 3 trial, TELLOMAK 3, in cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and Mycosis fungoides, anticipated to begin in the first half of 2026. Earlier Phase 2 TELLOMAK data demonstrated favorable safety, durable activity, and quality-of-life improvements, although new patient enrollment was temporarily paused in an earlier trial due to a partial clinical hold following a rare adverse event. Monalizumab, an anti-NKG2A immune checkpoint inhibitor, is being developed in collaboration with AstraZeneca. The Phase 3 PACIFIC-9 study in unresectable, Stage III non-small cell lung cancer (NSCLC) has completed enrollment, with key data expected in the second half of 2026. Additionally, interim data from the Phase 2 NeoCOAST-2 trial in resectable, early-stage NSCLC were presented in September 2024. However, a Phase 3 trial for head and neck cancer was discontinued following a futility analysis. IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, is partnered with AstraZeneca and is currently in a Phase 2 trial (MATISSE) for neoadjuvant non-small cell lung cancer. Another proprietary asset, IPH5301, a CD73-blocking antibody, is undergoing an investigator-sponsored Phase 1 trial in solid tumors, with an expansion cohort exploring combinations in HER2-positive breast and gastric cancers. The company’s innovative ANKET® platform yields multi-specific NK cell engagers, including IPH6101 (SAR443579), which is progressing into Phase 2 trials for acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplasia, with Innate having regained its rights from Sanofi in April 2025, alongside a Sanofi equity investment. Another ANKET® program, IPH6501 (CD20-targeting), is entering clinical trials for non-Hodgkin lymphoma, supported by an investment from the Institute for Follicular Lymphoma Innovation. Furthermore, IPH4502, a proprietary Nectin-4 antibody-drug conjugate (ADC), is moving into Phase 1 clinical testing for various advanced solid tumors. Innate Pharma, established in 1999 and headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, continues to strategically prioritize its most promising clinical assets and advance its preclinical research, adapting to the funding environment.
Company News
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Target Price of $6.67
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma Reports First Half 2026 Business Update and Financial Results
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
Innate Pharma Announces Conference Call and Webcast
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)